On Tuesday, September 21, the U.S. Food and Drug Administration approved fingolimod capsules (Gilenya, Novartis International AG) for reducing the frequency of relapses and delaying the accumulation of physical disability in relapsing forms of MS, making it the first oral disease-modifying therapy for the treatment of MS. According to Novartis, the drug will be available for prescription in coming weeks.